A Single Microneedle Patch Could Deliver a Month's Worth of Semaglutide Without Any Injections
A programmable microneedle patch system delivers semaglutide in four timed-release bursts over one month from a single skin application, potentially replacing weekly injections with one painless patch.
Quick Facts
What This Study Found
A single-application microneedle patch with 4 programmable core-shell pixels achieves sequential weekly semaglutide release over one month, simulating 4 separate bolus injections from one painless skin application.
Key Numbers
Semaglutide has a half-life of approximately 7 days. The patch system delivers multiple programmed doses from a single application.
How They Did This
Preclinical development of a programmable scheduled release microneedle (PSR-MN) system. Each 2cm × 2cm patch contains 4 pixel units (1cm² each) with core-shell architecture enabling time-programmed drug release at 7-day intervals.
Why This Research Matters
Needle phobia and injection burden are major barriers to GLP-1 drug adherence. A painless, single-application monthly patch could dramatically improve patient compliance and make obesity treatment more accessible, while also reducing medical waste and the need for healthcare facilities.
The Bigger Picture
Drug delivery innovation is key to maximizing the impact of effective medications. As GLP-1 drugs transform obesity treatment, making them easier and less painful to use could expand access to millions more patients worldwide, particularly in settings without regular access to healthcare providers for injections.
What This Study Doesn't Tell Us
Preclinical stage — no human trials reported. The precise release kinetics in human skin may differ from lab testing. Scalability and manufacturing costs are not addressed. Skin reactions to the patch over a month of wear are not characterized. Storage stability of the patch needs validation.
Questions This Raises
- ?How does the pharmacokinetic profile of patch delivery compare to subcutaneous injection in clinical settings?
- ?Can the patch maintain therapeutic drug levels as reliably as injections?
- ?What are the manufacturing costs and scalability challenges for this technology?
Trust & Context
- Key Stat:
- 1 patch = 4 weekly doses Single-application microneedle patch replaces one month of semaglutide injections through programmed sequential release
- Evidence Grade:
- Preliminary evidence from preclinical development. Proof-of-concept for the delivery technology but no human pharmacokinetic or efficacy data yet.
- Study Age:
- Published in 2024. Represents cutting-edge drug delivery technology for peptide therapeutics.
- Original Title:
- Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.
- Published In:
- Advanced therapeutics, 7(9) (2024)
- Authors:
- Singh, Parbeen, Vinikoor, Tra, Sharma, Nidhi, Nelson, Nicole, Prasadh, Somasundaram, Oiknine, Ralph, Nguyen, Thanh Duc
- Database ID:
- RPEP-09278
Evidence Hierarchy
Frequently Asked Questions
How do microneedle patches work?
Microneedle patches have tiny, dissolving needles on their surface — small enough to penetrate only the outermost skin layer without reaching pain-sensing nerves. The drug is contained within these needles or in reservoirs beneath them, and it's released into the skin as the needles dissolve.
When could this be available?
This technology is still in early development. It would need to go through human clinical trials to prove it delivers semaglutide as effectively as injection and to verify safety. This process typically takes several years.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09278APA
Singh, Parbeen; Vinikoor, Tra; Sharma, Nidhi; Nelson, Nicole; Prasadh, Somasundaram; Oiknine, Ralph; Nguyen, Thanh Duc. (2024). Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.. Advanced therapeutics, 7(9). https://doi.org/10.1002/adtp.202400028
MLA
Singh, Parbeen, et al. "Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.." Advanced therapeutics, 2024. https://doi.org/10.1002/adtp.202400028
RethinkPeptides
RethinkPeptides Research Database. "Single-Administration Self-Boosting Microneedle Patch for Th..." RPEP-09278. Retrieved from https://rethinkpeptides.com/research/singh-2024-singleadministration-selfboosting-microneedle-patch
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.